Trial Profile
A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms MITO16-MANGO2
- 23 Mar 2023 Planned End Date changed from 1 Nov 2022 to 1 Dec 2024.
- 23 Mar 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
- 03 Mar 2021 Planned End Date changed from 1 Jul 2018 to 1 Nov 2022.